Palliative care in patients with multiple sclerosis

Neurologic Clinics

Volumn 19, Issue 4, 2001, Pages 801-827

  Ben Zacharia, Aliza Bitton ^a   Lublin, Fred D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; BACLOFEN; BETA1A INTERFERON; CARBAMAZEPINE; CYCLOOXYGENASE 2 INHIBITOR; DESIPRAMINE; FENTANYL; FLUOXETINE; GABAPENTIN; GLATIRAMER; HYDROMORPHONE; IMIPRAMINE; INTERFERON BETA SERINE; MITOXANTRONE; MODAFINIL; MORPHINE; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; OXYCODONE; PEMOLINE; PHENYTOIN; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

BLADDER DYSFUNCTION; BONE DEFECT; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DEMYELINATING DISEASE; DISABILITY; DRUG INDUCED DISEASE; DYSPHAGIA; FATIGUE; HUMAN; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; PAIN; PALLIATIVE THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SOCIAL SUPPORT; SPASTICITY; SPEECH DISORDER; VISUAL IMPAIRMENT;

EID: 0035172473     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(05)70048-7     Document Type: Article

References (121)

1. A prospective study on the natural history of multiple sclerosis: Clues to the conduct and interpretation of clinical trials
2. Impaired motor function and sensory integrity associated with progressive disorders of the CNS in adulthood
3. Abnormalities of detrusor and sphincter function in multiple sclerosis
4. Revised estimate of the prevalence of multiple sclerosis in the United States
5. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients
6. Quality of life among patients with multiple sclerosis and their caregivers
7. The effects of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis
8. Physical modalities for complex regional pain syndrome
9. Communication: Language and pragmatics
10. Alternative medicine and multiple sclerosis: An objective review from an American perspective
11. Brief communications: Utilization of unconventional treatments by persons with MS: Is it alternative or complementary?
12. Swallowing and speaking: Challenges for the MS patient
13. Palliative care and end of life issues
14. Suicide and MS
15. The management of multiple sclerosis patients
16. Amantidine treatment of fatigue associated with multiple sclerosis
17. Multiple sclerosis treatment trial precipitates divorce
18. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients
19. Clinical and rehabilitation outcome measures
20. Bladder dysfunction
21. Dysphagia in children, adults, and geriatrics: Dysphagia caused by neurologic deficits
22. Recent developments in the assessment of quality of life in multiple sclerosis
23. What do we really know about cognitive dysfunction, affective disorders, and stress in multiple sclerosis? A practitioner guide
24. The impact of fatigue on patients with multiple sclerosis
25. Course of illness and prognosis of multiple sclerosis. 1. The natural illness course
26. Course of illness and prognosis of multiple sclerosis: Predictive value of clinical and paraclinical factors
27. Sexuality
28. Symptomatic fatigue in multiple sclerosis
29. The impact of inpatient rehabilitation on progressive multiple sclerosis
30. Clinical snaphot: Multiple sclerosis
31. Cognition and behavioral patterns
32. Neurologic abnormalities in multiple sclerosis
33. Research priorities for nurses caring for persons with multiple sclerosis: Nursing research specialty group of the consortium of multiple sclerosis centers
34. The social impact of multiple sclerosis: A study of 305 patients and their relatives
35. New strategies, new hope: Meeting the challenge of multiple sclerosis
36. New strategies, new hopes: Meeting the challenge for multiple sclerosis: Treating the person and the disease
37. Multiple sclerosis in Australia: Prognostic factors
38. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors
39. Urodynamics and multiple sclerosis
40. Improving quality of life for people with chronic conditions: The example of tai chi and multiple sclerosis
41. Intramuscular Interferon Beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
42. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment
43. Survival and predictors of disability in Turkish multiple sclerosis patients
44. Multiple sclerosis and pain: A medical focus
45. Prognosis in multiple sclerosis
46. Fatigue in multiple sclerosis: Reducing the impact through comprehensive management
47. Clinical practice issues in MS-related fatigue: A roundtable discussion
48. Fatigue in multiple sclerosis
49. Fatigue therapy in multiple sclerosis: Results of a double blind, randomized, parallel trial of amantidine, pemoline, and placebo
50. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale, EDSS
51. World-wide trends in multiple sclerosis mortality
52. Cognitive and emotional disorders
53. Prognostic factors for survival in multiple sclerosis
54. Dysphagia
55. Defining the clinical course of multiple sclerosis: Results of an international survey
56. Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference
57. Pain in multiple sclerosis: An overview of its nature and management
58. Quality of life: A concept analysis
59. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
60. Urodynamic findings and long-term outcome management of patients with multiple sclerosis: Induced lower urinary tract dysfunction
61. Regulating physician assisted death
62. Pain syndromes in multiple sclerosis
63. Pain in multiple sclerosis
64. Pain in central and peripheral demyelinating disorders Multiple Sclerosis and Guillain Barré Syndrome
65. Rationale for early treatment with interferon beta-1a in relapsing remitting multiple sclerosis
66. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom: Cost of multiple sclerosis study group
67. The history of multiple sclerosis
68. Ethical issues in multiple sclerosis
69. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
70. Sildenafil for women patients with antidepressant-induced sexual dysfunction
71. Impact of aerobic training on fitness and quality of life in multiple sclerosis
72. Drug treatment of multiple sclerosis
73. New diagnostic criteria for multiple sclerosis, guidelines for research protocols
74. Physician assisted suicide in Alzheimer's disease
75. Provigil (Modafinil): Efficacy and safety for the treatment of fatigue in patients with multiple sclerosis
76. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue
77. Psychosocial and neurologic predictors of mental health in multiple sclerosis
78. Reflections on the treatment of seizures in the elderly population
79. A doctor's journey to the side
80. Life expectancy in patients attending multiple sclerosis clinics
81. Cause of death in patients attending multiple sclerosis clinics
82. Antidepressants, old and new: A review of their adverse effects and toxicity in overdose
83. Sexual dysfunction
84. Symptomatic therapy of multiple sclerosis
85. The North American Research Consortium on Multiple Sclerosis Outcomes study group: Reliability and validity of two self-report measures of impairment and disability for MS
86. Short-term prognosis in early relapsing-remitting multiple sclerosis
87. Role of limited evaluation and aggressive medical management in multiple sclerosis: A review of 113 patients
88. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients
89. Dysarthria
90. Suicide and multiple sclerosis: An epidemiological investigation
91. Acute and chronic pain syndromes in multiple sclerosis
92. Multiple sclerosis update
93. Multiple sclerosis: Symptomatic treatment
94. 4-Aminopyridine in patients with multiple sclerosis: Dosage and serum level related to efficacy and safety
95. Multiple sclerosis: Side effects of interferon beta therapy and their management
96. The pain experience of a multiple sclerosis population: A descriptive study
97. The natural history of multiple sclerosis
98. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability
99. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course
100. The natural history of multiple sclerosis
101. A double blind randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis
102. Long-term and short-term outcome of multiple sclerosis: A 3-year follow-up study
103. Neuroepidemiology: Epidemiology of multiple sclerosis
104. Neuropsychologic status in multiple sclerosis after treatment with glatiramer
105. Clinical experience with donepezil (Aricept) in the UK
106. Linking clinical variables with health related quality of life: A conceptual model of patient outcomes
107. What people with newly diagnosed multiple sclerosis (and their families and friends) need to know
108. Spastic paresis